Skip to Content

Duetact Approval History

  • FDA approved: Yes (First approved July 31st, 2006)
  • Brand name: Duetact
  • Generic name: pioglitazone HCl and glimepiride
  • Dosage form: Tablets
  • Company: Takeda Pharmaceuticals North America, Inc.
  • Treatment for: Diabetes, Type 2

Duetact is a combination of pioglitazone, which directly targets insulin resistance, and glimepiride, a sulfonylurea that acts primarily by increasing the amount of insulin produced by the pancreas. Duetact is indicated for the treatment of type 2 diabetes.

Development History and FDA Approval Process for Duetact

Jul 31, 2006Approval Duetact Takeda Pharmaceuticals North America, Inc. - Treatment for Type 2 Diabetes
Jun 30, 2005Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication Containing Pioglitazone HCl and Glimepiride

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.